Skip to main content

Table 4 Unadjusted and adjusted hazards for death by PTH change group (quartile) for all patients and stratified by baseline PTH

From: Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study

Death

PTH change group

Unadjusted

Adjusted

All patients

HR (95% CI)

P

HR (95% CI)

P

No PTH reduction

1.15 (0.89-1.49)

0.3

1.23 (0.94-1.61)

0.1

Quartile 1

Referent

 

Referent

 

Quartile 2

1.06 (0.79-1.42)

0.7

1.05 (0.78-1.41)

0.8

Quartile 3

1.01 (0.75-1.36)

0.9

0.95 (0.71-1.29)

0.7

Quartile 4

1.20 (0.91-1.60)

0.2

1.03 (0.77-1.39)

0.8

Baseline PTH 300-600 pg/mL

No PTH reduction

0.98 (0.67-1.43)

0.9

1.05 (0.70-1.55)

0.8

Quartile 1

Referent

 

Referent

 

Quartile 2

1.06 (0.69-1.62)

0.8

1.09 (0.70-1.69)

0.7

Quartile 3

1.08 (0.71-1.65)

0.7

0.98 (0.63-1.52)

0.9

Quartile 4

1.06 (0.69-1.63)

0.8

0.92 (0.59-1.44)

0.7

Baseline PTH > 600 pg/mL

No PTH reduction

1.36 (0.95-1.94)

0.1

1.47 (1.02-2.13)

0.04

Quartile 1

Referent

 

Referent

 

Quartile 2

1.06 (0.71-1.59)

0.8

1.04 (0.69-1.56)

0.9

Quartile 3

0.95 (0.63-1.43)

0.8

0.90 (0.59-1.37)

0.6

Quartile 4

1.32 (0.91-1.94)

0.2

1.16 (0.78-1.73)

0.5

  1. Patients were grouped based on quartiles of PTH decrease from first cinacalcet prescription. Patients whose PTH levels increased or remained unchanged were assigned to “no PTH reduction” group.
  2. CI, confidence interval; HR, hazard ratio; PTH, parathyroid hormone.